RU97117084A - APPLICATION OF OXIDE, NITROGEN OR NITROXIDE OXIDE INHIBITOR DONORS FOR REGULATING THE DISCOVERY AND EXTENSION OF THE UTERINE NECK - Google Patents

APPLICATION OF OXIDE, NITROGEN OR NITROXIDE OXIDE INHIBITOR DONORS FOR REGULATING THE DISCOVERY AND EXTENSION OF THE UTERINE NECK

Info

Publication number
RU97117084A
RU97117084A RU97117084/14A RU97117084A RU97117084A RU 97117084 A RU97117084 A RU 97117084A RU 97117084/14 A RU97117084/14 A RU 97117084/14A RU 97117084 A RU97117084 A RU 97117084A RU 97117084 A RU97117084 A RU 97117084A
Authority
RU
Russia
Prior art keywords
use according
estra
nitric oxide
inhibitor
phenyl
Prior art date
Application number
RU97117084/14A
Other languages
Russian (ru)
Other versions
RU2199346C2 (en
Inventor
Хвалиш Кристоф
Э.Гарфильд Роберт
Original Assignee
Шеринг Аг
Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шеринг Аг, Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем filed Critical Шеринг Аг
Publication of RU97117084A publication Critical patent/RU97117084A/en
Application granted granted Critical
Publication of RU2199346C2 publication Critical patent/RU2199346C2/en

Links

Claims (1)

1. Применение доноров и/или субстратов оксида азота или ингибиторов оксида азота для производства лекарственного средства для регуляции расширения и/или растяжения шейки матки.1. The use of donors and / or substrates of nitric oxide or nitric oxide inhibitors for the manufacture of a drug to regulate the expansion and / or stretching of the cervix. 2. Применение по п. 1 или (а) по меньшей мере одного донора и/или субстрата оксида азота для получения лекарственного средства, который при местном введении внутришеечно или внутривагинально вызывает созревание шейки матки, или (б) по меньшей мере одного ингибитора оксида азота для получения лекарственного средства, который при местном введении внутришеечно или внутривагинально ингибирует созревание шейки матки при лечении недостаточности шейки матки и преждевременных родов. 2. The use according to claim 1 or (a) of at least one donor and / or substrate of nitric oxide for the manufacture of a medicament which, when topically administered intracellularly or intravaginally, causes maturation of the cervix, or (b) of at least one nitric oxide inhibitor to obtain a drug that, when administered topically, intra cervically or intravaginally inhibits cervical ripening in the treatment of cervical insufficiency and preterm labor. 3. Применение по п.2, в котором донор и/или субстрат оксида азота используют в сочетании с по меньшей мере одним антипрогестином, простагландином и/или цитокином. 3. The use according to claim 2, in which the donor and / or substrate of nitric oxide is used in combination with at least one antiprogestin, prostaglandin and / or cytokine. 4. Применение по п. 2, в котором ингибитор оксида азота используют в сочетании с по меньшей мере одним прогестином и/или ингибитором циклооксигеназы (ингибиторы СОХ-1 и СОХ-2). 4. The use according to claim 2, wherein the nitric oxide inhibitor is used in combination with at least one progestin and / or cyclooxygenase inhibitor (COX-1 and COX-2 inhibitors). 5. Применение по п. 2 или 3 для вызывания родов в срок. 5. The use of claim 2 or 3 to induce childbirth on time. 6. Применение по п. 2 или 3 для вызывания родов в связи с патологической беременностью. 6. The use according to claim 2 or 3 for inducing childbirth in connection with a pathological pregnancy. 7. Применение по п. 2 или 3 для вызывания родов в связи с внутриматочной гибелью плода. 7. The use according to claim 2 or 3 for inducing labor in connection with intrauterine death of the fetus. 8. Применение по п. 2 или 3 в случаях аборта. 8. The use according to claim 2 or 3 in cases of abortion. 9. Применение по п. 2 или 3 для вызывания преждевременных родов. 9. Use according to claim 2 or 3 for inducing preterm labor. 10. Применение по п. 2 или 3 для регуляции продолжительных родов. 10. The use according to claim 2 or 3 for the regulation of prolonged labor. 11. Применение по п. 2 или 3 для вызывания созревания шейки матки небеременных женщин или беременных женщин при хирургической или диагностической процедуре. 11. The use according to claim 2 or 3 for causing cervical ripening of non-pregnant women or pregnant women during a surgical or diagnostic procedure. 12. Применение по п.2 или 3 для вызывания созревания шейки матки у женщин, которых подвергают оплодотворению
13. Применение по п.2 или 4 для лечения недостаточности шейки матки.12. The use according to claim 2 or 3 for causing cervical ripening in women who are fertilized.
13. The use according to claim 2 or 4 for the treatment of cervical insufficiency. 14. Применение по п. 2 или 4 для лечения в случае угрозы преждевременных родов. 14. The use according to claim 2 or 4 for treatment in case of a threat of premature birth. 15. Применение по п. 2, где в качестве субстрата и/или донора оксида азота используют по меньшей мере одно соединение, выбранное из L-аргинина, нитропруссида натрия, нитроглицерина, глицерилтринитрата, SIN-1, изосорбидмононитрата, изосорбиддинитрата. 15. The use according to claim 2, wherein at least one compound selected from L-arginine, sodium nitroprusside, nitroglycerin, glyceryl trinitrate, SIN-1, isosorbidmononitrate, isosorbiddinitrate is used as a substrate and / or donor of nitric oxide. 16. Применение по п. 2, где в качестве ингибитора оксида азота используют по меньшей мере одно соединение, выбран- ное из метилового эфира NG-нитро-L-аргинина (L-NAME), NG-моноэтил-L-аргинина (LММА), N-иминоэтил-L-арнитина (L-NIO), L-монометил-L-аргинина (L-NNМА), L-NG-метил-аргинина (LNМА), NW-нитро-L-аргинина (L-NA) и амино-гуанидина. 16. The use according to claim 2, wherein at least one compound selected from NG-nitro-L-arginine methyl ester (L-NAME), NG-monoethyl-L-arginine (LMMA) is used as an inhibitor of nitric oxide , N-iminoethyl-L-arnitine (L-NIO), L-monomethyl-L-arginine (L-NNMA), L-NG-methyl-arginine (LNMA), NW-nitro-L-arginine (L-NA) and amino guanidine. 17. Применение по п. 3, где в качестве антипрогрестина используют по меньшей мере одно соединение, выбранное из онопристон
(11β-[4-(диметиламино)фенил]-17α-гидрокси-17β-(гидроксипропил)-13α-эстра-4,9-диен-3-она),
RU486 (11β-[4-(диметиламино)фенил]-17β-гидрокси-17α-(1-пропенил)-эстра-4,9-диен-3-она),
(Z)-11β-[4-(диметиламино)фенил]-17β-гидрокси-17α-(3-гидрокcи-1-пpoпeнил)-эстра-4-eн-3-oнa (ЕР-А 0 404 283),
11β-(4-ацетилфенил)17β-гидрокси17α-(1-пропинил) эстра-4,9-диен-3-она (ЕР-А, 0 190 759),
4',5'-дигидро-11β--[4-(диметиламино)фенил]-6β-метилспиро[эстра-4,9-диен-17β,2′(3'Н )-фуран]-3-она,
4', 5'-дигидро-11β-[4-(диметиламино)фенил] -7β-метилспиро[эстpa-4,9-диeн-17β,2′(3'H) -фуpaн]-3-oнa,
11β-(4-ацетилфенил)-19,24-динор-17,23-эпокси-17α-хола- 4,9,20-триен-3-она
(Е)-11β-[4[[(ацетокси)имино]метил]фенил]-17β-метокси-17α-мето- ксиметил) эстра-4,9-диен-3-она,
(E)-11β-[4-[[[(этoкcикapбoнил)oкcи] иминo] мeтил] фeнил] -17β- -метокси-17α(метоксиметил) эстра-4,9-диен-3-она.17. The use according to claim 3, wherein at least one compound selected from onopristone is used as an antiprogestin.
(11β- [4- (dimethylamino) phenyl] -17α-hydroxy-17β- (hydroxypropyl) -13α-estra-4,9-diene-3-one),
RU486 (11β- [4- (dimethylamino) phenyl] -17β-hydroxy-17α- (1-propenyl) -estra-4,9-diene-3-one),
(Z) -11β- [4- (dimethylamino) phenyl] -17β-hydroxy-17α- (3-hydroxy-1-propylene) -estra-4-en-3-ona (EP-A 0 404 283),
11β- (4-acetylphenyl) 17β-hydroxy17α- (1-propynyl) estra-4,9-dien-3-one (EP-A, 0 190 759),
4 ', 5'-dihydro-11β - [4- (dimethylamino) phenyl] -6β-methylspiro [estra-4,9-diene-17β, 2 ′ (3'H) -furan] -3-one,
4 ', 5'-dihydro-11β- [4- (dimethylamino) phenyl] -7β-methylspiro [estra-4,9-diene-17β, 2'(3'H) -furan] -3-ona,
11β- (4-acetylphenyl) -19,24-dinor-17,23-epoxy-17α-hola-4,9,20-trien-3-one
(E) -11β- [4 [[((acetoxy) imino] methyl] phenyl] -17β-methoxy-17α-methoxymethyl) estra-4,9-diene-3-one,
(E) -11β- [4 - [[[((Ethoxycarbonyl) oxy] imo] methyl) phenyl] -17β-methoxy-17α (methoxymethyl) estra-4,9-diene-3-one. 18. Применение по п. 3, где в качестве простагландина используют PGE2 или Гемепрост по пункту 3.18. The use according to claim 3, wherein, as a prostaglandin, PGE 2 or Gemeprost under item 3 is used. 19. Применение по п. 3, где в качестве цитокина используют интелейкин-8 или интерлейкин-1β
20. Применение по п. 4, где в качестве прогестина используют прогестерон.19. The use according to claim 3, wherein Intelikin-8 or interleukin-1β is used as a cytokine.
20. The use according to claim 4, wherein progesterone is used as a progestin. 21. Применение по п. 4, где в качестве ингибитора циклоксигеназы используют аспирин. 21. The use according to claim 4, wherein aspirin is used as a cycloxygenase inhibitor. 22. Применение по п. 4, где в качестве ингибитора СОХ-2 используют флусолид. 22. The use according to claim 4, wherein flusolid is used as a COX-2 inhibitor.
RU97117084/14A 1995-03-14 1996-03-14 Application of donors of nitrogen oxide or inhibitors of nitrogen oxide for regulation of uterus cervix opening and stretching RU2199346C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95250059 1995-03-14
EP95250059.3 1995-03-14

Publications (2)

Publication Number Publication Date
RU97117084A true RU97117084A (en) 1999-08-10
RU2199346C2 RU2199346C2 (en) 2003-02-27

Family

ID=8221039

Family Applications (1)

Application Number Title Priority Date Filing Date
RU97117084/14A RU2199346C2 (en) 1995-03-14 1996-03-14 Application of donors of nitrogen oxide or inhibitors of nitrogen oxide for regulation of uterus cervix opening and stretching

Country Status (26)

Country Link
US (1) US6333350B1 (en)
EP (1) EP0814785B1 (en)
JP (1) JP4579349B2 (en)
KR (2) KR100434238B1 (en)
CN (1) CN1151781C (en)
AT (1) ATE377417T1 (en)
AU (1) AU713172B2 (en)
CA (1) CA2214779A1 (en)
CZ (1) CZ292395B6 (en)
DE (1) DE69637313T2 (en)
ES (1) ES2297838T3 (en)
HU (1) HUP9800826A3 (en)
ID (1) ID20742A (en)
IL (1) IL117496A (en)
IS (1) IS4555A (en)
MX (1) MX9707007A (en)
MY (1) MY116500A (en)
NO (1) NO318598B1 (en)
NZ (1) NZ305169A (en)
PL (1) PL183461B1 (en)
RU (1) RU2199346C2 (en)
SK (1) SK124197A3 (en)
TW (1) TW421594B (en)
UA (1) UA57703C2 (en)
WO (1) WO1996028145A1 (en)
ZA (1) ZA962089B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK124197A3 (en) 1995-03-14 1998-06-03 Schering Ag Use of nitric oxide donors or nitric oxide inhibitors for regulating cervical dilatation and extensibility
EP0889724A1 (en) * 1996-02-27 1999-01-13 Rpms Technology Limited Cox-2 selective inhibitors for managing labour and uterine contractions
US6232434B1 (en) 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
DE19809845A1 (en) 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituted 11beta-benzaldoxime-estra-4,9-diene-carbonic acid thiol esters, processes for their preparation and pharmaceutical preparations containing these compounds
ITMI20002117A1 (en) * 2000-09-29 2002-03-29 Ibsa Inst Biochimique Sa USE OF SODIUM NITROPRUSSIATE IN OBSTETRICS AND GYNECOLOGY
WO2005023189A2 (en) * 2003-09-03 2005-03-17 Pharmacia Corporation Method of cox-2 selective inhibitor and nitric oxide-donating agent
WO2006089561A1 (en) * 2005-02-23 2006-08-31 Abbas Abdelsalam Ghazi Pharmaceutical compositions containing organic acids useful for softening and ripening uterine cervix.
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
CN102283827A (en) * 2008-10-16 2011-12-21 四川维信医药科技有限责任公司 New application of isosorbide mononitrate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508045A (en) 1992-10-09 1996-04-16 The Regents Of The University Of California Method and agents for control and management of labor during pregnancy
NZ276105A (en) * 1993-11-16 2001-04-27 Schering Ag Use of nitric oxide synthase substrate and/or nitric oxide donor optionally with other compounds to prevent uterine contraction or a nitric oxide inhibitor to stimulate uterine contraction
US5550369A (en) 1994-02-28 1996-08-27 Electro-Pro, Inc. Triangulation position detection method and apparatus
SK124197A3 (en) 1995-03-14 1998-06-03 Schering Ag Use of nitric oxide donors or nitric oxide inhibitors for regulating cervical dilatation and extensibility

Similar Documents

Publication Publication Date Title
US5595970A (en) Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors
US20010056068A1 (en) Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
RU97117084A (en) APPLICATION OF OXIDE, NITROGEN OR NITROXIDE OXIDE INHIBITOR DONORS FOR REGULATING THE DISCOVERY AND EXTENSION OF THE UTERINE NECK
SK121996A3 (en) Progesterone antagonists useful for preparing medicaments for treating dysfunctional uterine bleeding
NO314066B1 (en) Use of a compound with progesterone antagonistic (PA) action and at least ± one compound with antiestrogen (AÖ) action preparation of an agent intended for combined use for contraception in women
ES2397983T3 (en) Long-cycle multiphase oral contraceptive procedure
PT787002E (en) Competitive progesterone antagonists for regulating female fertility as required
RU2199346C2 (en) Application of donors of nitrogen oxide or inhibitors of nitrogen oxide for regulation of uterus cervix opening and stretching
US6100249A (en) Use of aspirin for the manufacture of a medicament for implanting an embryo into the uterine endometrium
US5962413A (en) Treatment of uterine contractility disorders with a nitric oxide synthase substrate and/or donor, or a nitric oxide inhibitor
PL178174B1 (en) Treatment of uterus contractility disorders by means of nitrogen oxide synthase substrates and/or nitrogen oxide donors or nitrogen oxide inhibitor
ABRAHAM Primary dysmenorrhea
WO1996028145A9 (en) Use of nitric oxide donors or nitric oxide inhibitors for regulating cervical dilatation and extensibility
EA006805B1 (en) Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives
US20050215535A1 (en) Sequential SPRM/progestin treatment
WO1998040076A1 (en) Compositions for the treatment of climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with partial estrogen antagonists
RU96113138A (en) METHOD OF TREATMENT OF DAMAGE REDUCTION OF UTERUS WITH SUBSTRATE OF NITROGEN OXIDE-SYNTHASE AND / OR NITROGEN OXIDE DONOR OR NITROGEN OXIDE INHIBITOR
WO2003099333A1 (en) Methods of controlling fertility, cancers and reproductive tract diseases
AU5765901A (en) Treatment of uterine contractility disorders with a nitric oxide synthase substrate and/or donor, or a nitric oxide inhibitor